AZN:NYSE
AstraZeneca PLC (US)
$161.43
arrow_downward
-2.02%(-3.32) 1D
Sep 4, 1:03:48 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
$162.82
High
$163.78
Low
$161.40
Mkt. cap
250.69B
Avg. vol.
3.88M
Volume
997.56K
Dividend
2.00%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
24.13
52-wk high
$212.71
52-wk low
$72.90
EPS
$6.69
Beta
0.28
Shares outstanding
1.55B
No. of employees
96K
Open
$162.82
High
$163.78
Low
$161.40
Mkt. cap
250.69B
Avg. vol.
3.88M
Volume
997.56K
Dividend
2.00%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
24.13
52-wk high
$212.71
52-wk low
$72.90
EPS
$6.69
Beta
0.28
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
AD HOC NEWS
·
42 minutes ago
AstraZeneca stock edges higher as investors eye oncology milestones and valuation gap
GuruFocus
·
4 hours ago
AZN Looks 9.4% Undervalued on GF Value™ Amid Strong Dividend Pro
www.marketscreener.com
·
4 hours ago
AstraZeneca: Share price weakness of late, should be capitalised on
Kalkine Media
·
8 hours ago
Why Did AstraZeneca (LSE:AZN) Sit Among London's Heaviest Fallers Today?
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com